Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 4/20 | 0.50 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.47 |
| ▸ | ZAP70 | P43403 | 6/20 | 0.45 |
| ▸ | ULK1 | O75385 | 1/20 | 0.43 |
| ▸ | CDK7 | P50613 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.41 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL375527 | 0.89 | IGF1R (0.50) | IGF1RALKZAP70ULK1CDK7 | |
| SCHEMBL4103133 | 0.88 | IGF1R (0.49) | IGF1RALKZAP70ULK1CDK7 | |
| SCHEMBL29190691 | 0.88 | ALK (0.59) | IGF1RALKZAP70ULK1CDK7 | |
| SCHEMBL375360 | 0.86 | ZAP70 (0.61) | IGF1RALKZAP70ULK1CDK7 | |
| SCHEMBL25056256 | 0.85 | ZAP70 (0.48) | IGF1RALKZAP70ULK1CDK7 | |
| SCHEMBL29214361 | 0.85 | CDK7 (0.60) | IGF1RALKCDK7CDK9 | |
| SCHEMBL31251181 | 0.85 | IGF1R (0.46) | IGF1RALKZAP70ULK1CDK7 | |
| SCHEMBL31251230 | 0.84 | CDK7 (0.53) | IGF1RALKZAP70ULK1CDK7 | |
| SCHEMBL4094489 | 0.83 | ZAP70 (0.48) | IGF1RALKZAP70ULK1CDK7 | |
| SCHEMBL375399 | 0.81 | ZAP70 (0.46) | IGF1RALKZAP70ULK1CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131436-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
| US-20090131436-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
| US-20090131436-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
| EP-1784392-A2 | PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006021454-A2 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131436-A1 | Pyrimidine Derivatives | DPYD, TYMP, TYMS | IGF1R 4608/4885ALK 2060/4885ZAP70 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.